IMM-H007

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 565453

CAS#: 1221412-23-2

Description: IMM-H007 is a novel lipid-lowering agent, increasing abca1 protein expression


Chemical Structure

img
IMM-H007
CAS# 1221412-23-2

Theoretical Analysis

MedKoo Cat#: 565453
Name: IMM-H007
CAS#: 1221412-23-2
Chemical Formula: C22H23N5O8
Exact Mass: 485.15
Molecular Weight: 485.453
Elemental Analysis: C, 54.43; H, 4.78; N, 14.43; O, 26.37

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Related CAS #: 1221412-23-2    

Synonym: IMM-H007; IMM H007; IMMH007; WS 070117; WS-070117; WS070117;

IUPAC/Chemical Name: N-(3-Hydroxyphenyl)adenosine 2',3',5'-triacetate

InChi Key: PIFNMFQDQJWHMO-HUUCEWRRSA-N

InChi Code: InChI=1S/C18H17N5O4/c1-11(24)26-8-14-5-6-15(27-14)23-10-21-16-17(19-9-20-18(16)23)22-12-3-2-4-13(25)7-12/h2-7,9-10,14-15,25H,8H2,1H3,(H,19,20,22)/t14-,15-/m1/s1

SMILES Code: OC1=CC(NC2=C3N=CN([C@H]4[CH][CH][C@H](COC(C)=O)O4)C3=NC=N2)=CC=C1

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >3 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 485.45 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Peng X, Li J, Wang M, Qu K, Zhu H. A novel AMPK activator improves hepatic lipid metabolism and leukocyte trafficking in experimental hepatic steatosis. J Pharmacol Sci. 2019 Jun 4. pii: S1347-8613(19)34163-5. doi: 10.1016/j.jphs.2019.05.008. [Epub ahead of print] PubMed PMID: 31253430.

2: Ge W, Zhang W, Gao R, Li B, Zhu H, Wang J. IMM-H007 improves heart function via reducing cardiac fibrosis. Eur J Pharmacol. 2019 Aug 15;857:172442. doi: 10.1016/j.ejphar.2019.172442. Epub 2019 Jun 7. PubMed PMID: 31181209.

3: Wang MJ, Peng XY, Lian ZQ, Zhu HB. The cordycepin derivative IMM-H007 improves endothelial dysfunction by suppressing vascular inflammation and promoting AMPK-dependent eNOS activation in high-fat diet-fed ApoE knockout mice. Eur J Pharmacol. 2019 Jun 5;852:167-178. doi: 10.1016/j.ejphar.2019.02.045. Epub 2019 Feb 28. PubMed PMID: 30826323.

4: Zhang ZL, Liu WQ, Deng XZ. Preclinical pharmacokinetic study of a novel lipid-lowering agent, IMM-H007. Eur Rev Med Pharmacol Sci. 2018 Dec;22(24):8939-8950. doi: 10.26355/eurrev_201812_16664. PubMed PMID: 30575938.

5: Gao F, Qian YJ, Chen FH, Zhu HB. Comparative analysis of stimulation and binding characteristics of adenosine analogs to AMP-activated protein kinase. J Asian Nat Prod Res. 2019 Sep;21(9):916-927. doi: 10.1080/10286020.2018.1484454. Epub 2018 Sep 6. PubMed PMID: 30187782.

6: Jin M, Guo N, Li T, Liu X, Sun S, Jin X, Zhu H, Qin H, Wang Y. Comprehensive characterization of in vitro and in vivo metabolites of 2',3',5' tri O acetyl N(6) (3 hydroxyphenyl) adenosine and study of the metabolites distribution in rats by combined methods of HPLC-DAD, off-line cryoNMR, and HPLC-QTOFMS. J Chromatogr B Analyt Technol Biomed Life Sci. 2018 Oct 1;1096:187-200. doi: 10.1016/j.jchromb.2018.08.028. Epub 2018 Aug 28. PubMed PMID: 30176508.

7: Li T, Sun S, Zhang J, Qu K, Yang L, Ma C, Jin X, Zhu H, Wang Y. Beneficial Metabolic Effects of 2',3',5'-Triacetyl-N(6)-(3-hydroxylaniline) adenosine in Multiple Biological Matrices and Intestinal Flora of Hyperlipidemic Hamsters. J Proteome Res. 2018 Aug 3;17(8):2870-2879. doi: 10.1021/acs.jproteome.8b00330. Epub 2018 Jun 29. PubMed PMID: 29925242.

8: Shi H, Wang Q, Yang L, Xie S, Zhu H. IMM-H007, a new therapeutic candidate for nonalcoholic fatty liver disease, improves hepatic steatosis in hamsters fed a high-fat diet. FEBS Open Bio. 2017 Aug 29;7(9):1379-1391. doi: 10.1002/2211-5463.12272. eCollection 2017 Sep. PubMed PMID: 28904866; PubMed Central PMCID: PMC5586352.

9: Ma A, Wang J, Yang L, An Y, Zhu H. AMPK activation enhances the anti-atherogenic effects of high density lipoproteins in apoE(-/-) mice. J Lipid Res. 2017 Aug;58(8):1536-1547. doi: 10.1194/jlr.M073270. Epub 2017 Jun 13. PubMed PMID: 28611100; PubMed Central PMCID: PMC5538277.

10: Ma A, Wang D, An Y, Fang W, Zhu H. Comparative transcriptomic analysis of mice liver treated with different AMPK activators in a mice model of atherosclerosis. Oncotarget. 2017 Mar 7;8(10):16594-16604. doi: 10.18632/oncotarget.15027. PubMed PMID: 28178661; PubMed Central PMCID: PMC5369987.

11: Jia Y, Wang B, Wu X, Li S, Hu J, Wang D, Zhu H, Li Y. Simultaneous quantification of 2',3',5'-tri-O-acetyl-N6-(3-hydroxylaniline)adenosine and its principal metabolites in hamster blood by LC-MS/MS and its application in pharmacokinetics study. J Chromatogr B Analyt Technol Biomed Life Sci. 2016 Jun 1;1022:46-53. doi: 10.1016/j.jchromb.2016.04.004. Epub 2016 Apr 2. PubMed PMID: 27082762.

12: Chen B, Li J, Zhu H. AMP-activated protein kinase attenuates oxLDL uptake in macrophages through PP2A/NF-κB/LOX-1 pathway. Vascul Pharmacol. 2016 Oct;85:1-10. doi: 10.1016/j.vph.2015.08.012. Epub 2015 Aug 19. PubMed PMID: 26297684.

13: Huang L, Fan B, Ma A, Shaul PW, Zhu H. Inhibition of ABCA1 protein degradation promotes HDL cholesterol efflux capacity and RCT and reduces atherosclerosis in mice. J Lipid Res. 2015 May;56(5):986-97. doi: 10.1194/jlr.M054742. Epub 2015 Mar 11. PubMed PMID: 25761370; PubMed Central PMCID: PMC4409288.

14: Zhao Z, Song G, Tian H, Yu Y, Tian X, Liu J, Yao S, Luo T, Qin S. Triacetyl-3-hydroxyphenyladenosine, a derivative of cordycepin, attenuates atherosclerosis in apolipoprotein E-knockout mice. Exp Biol Med (Maywood). 2012 Nov;237(11):1262-72. doi: 10.1258/ebm.2012.011401. PubMed PMID: 23239437.